







Florida Jurisprudence

Joseph Sowka, OD, FAAO, Diplomate



DISCLOSURE:


- Joseph Sowka, OD, in the past 24-months, has been a Consultant/ Speaker Bureau/ Advisory Board member B&L. Dr. Sowka has no direct financial interest in any of the diseases, products or instrumentation mentioned in this presentation. All relevant relationships have been mitigated. He is a co-owner of Optometric Education Consultants (www.optometricedu.com)*



The ideas, concepts, conclusions and perspectives presented herein reflect the opinions of the speaker; he has not been paid, coerced, extorted or otherwise influenced by any third party individual or entity to present information that conflicts with his professional viewpoints.


Disclaimer

- Every attempt has been made to present actual and factual information
- Information presented here is based on opinion, knowledge and experience
- The presenter is not an attorney and one should seek professional legal advice and/or representation for final clarification



OptometricEdu.com/Webinars





OptometricEdu.com/Webinars




- The objectives of this Association are to advance, improve, and enhance the vision care of the public
- To unite optometrists to encourage and assist in the improvement of the art and science of Optometry
- To elevate the standards and ethics of the profession of Optometry


OptometricEdu.com/Webinars



- To protect and defend the inalienable right of every person to freedom of choice of practitioner
- To restrict the practice of Optometry and any part of it to those who have been trained, qualified, and licensed to practice the profession
- To maintain an active affiliation with the AOA, and the Southern Council of Optometrists.


OptometricEdu.com/Webinars



FLORIDA Board of Optometry

OptometricEdu.com/Webinars



FLORIDA Board of Optometry

• **Mission:** To protect, promote & improve the health of all people in Florida through integrated state, county, & community efforts.

• **Vision:** To be the **Healthiest State** in the Nation

OptometricEdu.com/Webinars



FLORIDA Board of Optometry

- **Purpose:** To protect the public and make Florida the healthiest state in the nation through health care licensure, enforcement, and information.
- **Focus:** To be the nation's leader in quality health care regulation.
- **Values:** I CARE (Innovation, Collaboration, Accountability, Responsiveness, Excellence)

OptometricEdu.com/Webinars



FLORIDA Board of Optometry

The Florida Board of Optometry was established to ensure that every person engaged in the practice of optometry in this state meets minimum requirements for safe practice. It is the legislative intent that such persons who fall below minimum standards or who otherwise present a danger to the public shall be prohibited from practicing in this state.

OptometricEdu.com/Webinars


- The **Florida Board of Optometry** is composed of seven members appointed by the Governor and confirmed by the Senate.
- Five members of the board must be licensed practitioners actively practicing in this state.
- The remaining two members must be citizens of the state who are not, and have never been, licensed practitioners.
- Additionally, the consumer members may not be connected with the practice of optometry or with any other vision-related profession or business.
- At least one member of the board must be 60 years of age or older.

OptometricEdu.com/Webinars

Members of the Board




After the expiration of their terms, board members can continue to serve until they have been reelected, reappointed, or resign.



2013 Legislative Update- Prescription Authority

The 2013 legislative session brought very important changes for the practice of optometry. On April 19, 2013, Governor Rick Scott signed HB-239 into law

- Went into effect July 1, 2013
- Deleted ~~Topical~~ and added Ocular
- Defines Ocular Pharmaceutical Agent
- Defines Surgery



OptometricEdu.com/Webinars

HB 239

Defines Ocular Pharmaceutical Agent

"Ocular pharmaceutical agent" means a pharmaceutical agent that is administered topically or orally for the diagnosis or treatment of ocular conditions of the human eye and its appendages without the use of surgery or other invasive techniques.

OptometricEdu.com/Webinars

HB 239

Defines Surgery

"Surgery" means a procedure using an instrument, including a laser, scalpel, or needle, in which human tissue is cut, burned, scraped except as provided in s. 463.014(4), or vaporized, by incision, injection, ultrasound, laser, infusion, cryotherapy, or radiation. The term includes a procedure using an instrument which requires the closure of human tissue by suture, clamp, or other such device.

OptometricEdu.com/Webinars

HB 239

Defines what is not Surgery

OptometricEdu.com/Webinars

Surgery of any kind, ~~including the use of lasers~~, is expressly prohibited. Certified optometrists may remove superficial foreign bodies. For the purposes of this subsection, the term "superficial foreign bodies" means any foreign matter that is embedded in the conjunctiva or cornea but that which has not penetrated the globe

OptometricEdu.com/Webinars

- Notwithstanding the definition of surgery as provided in s. 463.002(6), a certified optometrist is not prohibited from providing any optometric care within the practice of optometry as defined in s. 463.002(7),
 - such as removing an eyelash by epilation,
 - probing an uninfamed tear duct in a patient 18 years of age or older,
 - blocking the puncta by plug,
 - or superficial scraping for the purpose of removing damaged epithelial tissue or superficial foreign bodies or taking a culture of the surface of the cornea or conjunctiva.

OptometricEdu.com/Webinars

4

The image shows two versions of the 'RELATIVE OPTOMETRIC BOARD EXAMINATION' form. The left form is titled 'To be completed by the candidate (applicant)' and the right form is titled 'To be completed by the board of optometry'. Both forms contain sections for 'Candidate Information', 'Examination Information', and 'Board Information'. The forms are filled out with handwritten and printed information.

Operation of Clinical Laboratories and Testing

The 2013 legislative session brought very important changes for the practice of optometry. On April 19, 2013, Governor Rick Scott signed HB-239 into law.

483.181 Acceptance, collection, identification, and examination of specimens

- A clinical laboratory licensed under this part must accept a human specimen submitted for examination by a practitioner licensed under chapter 458, chapter 459, chapter 460, chapter 461, chapter 462, chapter 463, s. 464.012, or chapter 466, if the specimen and test are the type performed by the clinical laboratory

HB 239

483.181 Acceptance, collection, identification, and examination of specimens

- A clinical laboratory may only refuse a specimen based upon a history of nonpayment for services by the practitioner
- A clinical laboratory shall not charge different prices for tests based upon the chapter under which a practitioner submitting a specimen for testing is licensed

Topical Ocular Pharmaceutical Agents added to Formulary

The Board of Optometry has added the following Topical Ocular Pharmaceutical Agents to the formulary...

HB 239

Defines Topical Formulary

- The board shall establish a formulary of topical ocular pharmaceutical agents that may be prescribed and administered by a certified optometrist.

HB 239

Defines Topical Formulary


The formulary shall consist of those topical ocular pharmaceutical agents that are appropriate to treat or diagnose ocular diseases and disorders and that which the certified optometrist is qualified to use in the practice of optometry. The board shall establish, add to, delete from, or modify the topical formulary by rule. Notwithstanding any provision of chapter 120 to the contrary, the topical formulary rule becomes ~~shall become~~ effective 60 days from the date it is filed with the Secretary of State.

HB 239

Topical Formulary

Any person who requests an addition, deletion, or modification of an authorized topical ocular pharmaceutical agent shall have the burden of proof to show cause why such addition, deletion, or modification should be made.


OptometricEdu.com/Webinars



Important Notice regarding Dextenza and Klarity-C
The Board of Optometry has approved Dextenza (dexamethasone ophthalmic insert) 0.4 mg and Klarity-C (cyclosporine) 0.1% for addition to Rule 64B13-18.002.

Klarity-C Drops® (Cyclosporine 0.1% ophthalmic emulsion PF)*

(9) MISCELLANEOUS
(a) Hydroxypropyl cellulose ophthalmic insert;
(b) Daptapazole – 0.5%;
(c) Cyclosporine emulsion or solution – **0.1%**;
(d) Polyvinyl pyrrolidone – drops 2.0%;
(e) Bimatoprost – .03%;
(f) Natamycin Ophthalmic Suspension 5%;
(g) Lifitegrast ophthalmic solution 5%; and,
(h) Cyclosporine 0.09% Ophthalmic Solution.
(i) Oxervate (Cenegermin-bkbj) 0.002%; and
(j) Oxymetazoline hydrochloride ophthalmic solution 0.1%.



Important Notice Regarding Oxervate
The Board of Optometry has approved Oxervate (Cenegermin-bkbj) 0.002% for addition to Rule 64B13-18.002.

(9) MISCELLANEOUS
(a) Hydroxypropyl cellulose ophthalmic insert;
(b) Daptapazole – 0.5%;
(c) Cyclosporine emulsion or solution – 0.1%;
(d) Polyvinyl pyrrolidone – drops 2.0%;
(e) Bimatoprost – .03%;
(f) Natamycin Ophthalmic Suspension 5%;
(g) Lifitegrast ophthalmic solution 5%; and,
(h) Cyclosporine 0.09% Ophthalmic Solution.
(i) **Oxervate (Cenegermin-bkbj) 0.002%;** and
(j) Oxymetazoline hydrochloride ophthalmic solution 0.1%.

oxervate® 0.002% (20 mcg/mL) (cenegermin-bkbj) ophthalmic solution

INDICATIONS AND USAGE
OXERVATE is a recombinant human nerve growth factor indicated for the treatment of neurotrophic keratitis. (1)

DOSAGE AND ADMINISTRATION
One drop of OXERVATE in the affected eye(s), 6 times per day at 2-hour intervals, for eight weeks. (2,3)



Public	\$21,969.47 \$21,969.47	Get this product
CVS Pharmacy	\$21,969.47 \$21,969.47	Get this product
Walmart	\$21,969.47 \$21,969.47	Get this product
Costco	\$21,969.47 \$21,969.47	Get this product
Walgreens	\$21,969.47 \$21,969.47	Get this product

Topical Ocular Pharmaceutical Agents added to Formulary

The Board of Optometry has added the following Topical Ocular Pharmaceutical Agents to the formulary...

(8) ANTI-GLAUCOMA AGENTS

(a) Beta Blockers.

1. betaxolol hydrochloride – 0.5%;
2. levobunolol hydrochloride – 0.5%;
3. metipranolol hydrochloride – 0.3%;
4. timolol maleate or hemihydrate – 0.5% (solution and gel, alone and in combination);
5. carteolol hydrochloride – 1.0%.

(b) Miotics, Direct-acting

1. carbachol – 3.0%;
2. **pilocarpine hydrochloride – 4.0%;**

Topical Ocular Pharmaceutical Agents added to Formulary

The Board of Optometry has added the following Topical Ocular Pharmaceutical Agents to the formulary...

(7) ANTIVIRAL AGENTS

- (a) trifluridine – 1.0%;
- (b) ganciclovir – 0.15%;
- (c) povidone-iodine ophthalmic solution – 5.0%
- (d) **acyclovir ophthalmic ointment – 3.0%**



Fera Pharmaceuticals Announces FDA Approval of Avaclyr[®] (acyclovir ophthalmic ointment)

NEW YORK—April 1, 2019—The US Food and Drug Administration (FDA) has approved Fera's New Drug Application (NDA) for Avaclyr[®] (acyclovir ophthalmic ointment) 3% for the treatment of herpetic keratitis. Orphan drug exclusivity was also granted, providing seven years of marketing exclusivity for the product.



(9) MISCELLANEOUS

- (a) hydroxypropyl cellulose ophthalmic insert;
- (b) dapiprazole – 0.5%;
- (c) cyclosporine emulsion or solution – 0.1%;
- (d) polyvinyl pyrrolidone solution – 2.0%;
- (e) bimatoprost – 0.03%;
- (f) natamycin ophthalmic suspension 5.0%;
- (g) lifitegrast ophthalmic solution 5.0%; and,
- (h) cenergermin-bkbj - 0.002%;
- (i) oxymetazoline hydrochloride ophthalmic solution 0.1%;
- (j) hypochlorous acid – 0.02%



The topical ocular pharmaceutical agents in the formulary include the following legend drugs alone or in combination in concentrations up to those specified, or any lesser concentration:

- (1) through (8) No change.
- (9) MISCELLANEOUS
- (a) through (j) No change.
- (k) varenicline solution – 0.03mg



Varenicline nasal spray approved as a treatment for dry eye disease

The FDA's approval of varenicline nasal spray 0.03 mg (Tyrvaia, Oyster Point Pharma) for the treatment of the signs and symptoms of dry eye disease (DED) brings to the management of this common condition a new therapeutic modality that is novel for both its mechanism of action and mode of administration. The new medication is recommended to be used twice daily, sprayed once into each nostril.

Topical Ocular Pharmaceutical Agents added to Formulary

Florida Last Steps on May 27, 2022

The Florida Board of Optometry has added the following Topical Ocular Pharmaceutical Agents to the formulary:

1. Latanoprost hydrochloride ophthalmic gel or solution - 0.01%
2. Latanoprost - 0.005%;
3. Bimatoprost - 0.03% per strip;
4. Travoprost - 0.004% per strip;
5. Bimatoprost - 0.03%;
6. Latanoprost hydrochloride ophthalmic solution - 0.01%;
7. Latanoprost - 0.005%;
8. Travoprost - 0.004%;
9. Bimatoprost - 0.03%;
10. Latanoprost - 0.005%;
11. Travoprost - 0.004%;
12. Bimatoprost - 0.03%;
13. Latanoprost - 0.005%;
14. Travoprost - 0.004%;
15. Bimatoprost - 0.03%;
16. Latanoprost - 0.005%;
17. Travoprost - 0.004%;
18. Bimatoprost - 0.03%;
19. Latanoprost - 0.005%;
20. Travoprost - 0.004%;
21. Bimatoprost - 0.03%;
22. Latanoprost - 0.005%;
23. Travoprost - 0.004%;
24. Bimatoprost - 0.03%;
25. Latanoprost - 0.005%;
26. Travoprost - 0.004%;
27. Bimatoprost - 0.03%;
28. Latanoprost - 0.005%;
29. Travoprost - 0.004%;
30. Bimatoprost - 0.03%;
31. Latanoprost - 0.005%;
32. Travoprost - 0.004%;
33. Bimatoprost - 0.03%;
34. Latanoprost - 0.005%;
35. Travoprost - 0.004%;
36. Bimatoprost - 0.03%;
37. Latanoprost - 0.005%;
38. Travoprost - 0.004%;
39. Bimatoprost - 0.03%;
40. Latanoprost - 0.005%;
41. Travoprost - 0.004%;
42. Bimatoprost - 0.03%;
43. Latanoprost - 0.005%;
44. Travoprost - 0.004%;
45. Bimatoprost - 0.03%;
46. Latanoprost - 0.005%;
47. Travoprost - 0.004%;
48. Bimatoprost - 0.03%;
49. Latanoprost - 0.005%;
50. Travoprost - 0.004%;
51. Bimatoprost - 0.03%;
52. Latanoprost - 0.005%;
53. Travoprost - 0.004%;
54. Bimatoprost - 0.03%;
55. Latanoprost - 0.005%;
56. Travoprost - 0.004%;
57. Bimatoprost - 0.03%;
58. Latanoprost - 0.005%;
59. Travoprost - 0.004%;
60. Bimatoprost - 0.03%;
61. Latanoprost - 0.005%;
62. Travoprost - 0.004%;
63. Bimatoprost - 0.03%;
64. Latanoprost - 0.005%;
65. Travoprost - 0.004%;
66. Bimatoprost - 0.03%;
67. Latanoprost - 0.005%;
68. Travoprost - 0.004%;
69. Bimatoprost - 0.03%;
70. Latanoprost - 0.005%;
71. Travoprost - 0.004%;
72. Bimatoprost - 0.03%;
73. Latanoprost - 0.005%;
74. Travoprost - 0.004%;
75. Bimatoprost - 0.03%;
76. Latanoprost - 0.005%;
77. Travoprost - 0.004%;
78. Bimatoprost - 0.03%;
79. Latanoprost - 0.005%;
80. Travoprost - 0.004%;
81. Bimatoprost - 0.03%;
82. Latanoprost - 0.005%;
83. Travoprost - 0.004%;
84. Bimatoprost - 0.03%;
85. Latanoprost - 0.005%;
86. Travoprost - 0.004%;
87. Bimatoprost - 0.03%;
88. Latanoprost - 0.005%;
89. Travoprost - 0.004%;
90. Bimatoprost - 0.03%;
91. Latanoprost - 0.005%;
92. Travoprost - 0.004%;
93. Bimatoprost - 0.03%;
94. Latanoprost - 0.005%;
95. Travoprost - 0.004%;
96. Bimatoprost - 0.03%;
97. Latanoprost - 0.005%;
98. Travoprost - 0.004%;
99. Bimatoprost - 0.03%;
100. Latanoprost - 0.005%;
101. Travoprost - 0.004%;
102. Bimatoprost - 0.03%;
103. Latanoprost - 0.005%;
104. Travoprost - 0.004%;
105. Bimatoprost - 0.03%;
106. Latanoprost - 0.005%;
107. Travoprost - 0.004%;
108. Bimatoprost - 0.03%;
109. Latanoprost - 0.005%;
110. Travoprost - 0.004%;
111. Bimatoprost - 0.03%;
112. Latanoprost - 0.005%;
113. Travoprost - 0.004%;
114. Bimatoprost - 0.03%;
115. Latanoprost - 0.005%;
116. Travoprost - 0.004%;
117. Bimatoprost - 0.03%;
118. Latanoprost - 0.005%;
119. Travoprost - 0.004%;
120. Bimatoprost - 0.03%;
121. Latanoprost - 0.005%;
122. Travoprost - 0.004%;
123. Bimatoprost - 0.03%;
124. Latanoprost - 0.005%;
125. Travoprost - 0.004%;
126. Bimatoprost - 0.03%;
127. Latanoprost - 0.005%;
128. Travoprost - 0.004%;
129. Bimatoprost - 0.03%;
130. Latanoprost - 0.005%;
131. Travoprost - 0.004%;
132. Bimatoprost - 0.03%;
133. Latanoprost - 0.005%;
134. Travoprost - 0.004%;
135. Bimatoprost - 0.03%;
136. Latanoprost - 0.005%;
137. Travoprost - 0.004%;
138. Bimatoprost - 0.03%;
139. Latanoprost - 0.005%;
140. Travoprost - 0.004%;
141. Bimatoprost - 0.03%;
142. Latanoprost - 0.005%;
143. Travoprost - 0.004%;
144. Bimatoprost - 0.03%;
145. Latanoprost - 0.005%;
146. Travoprost - 0.004%;
147. Bimatoprost - 0.03%;
148. Latanoprost - 0.005%;
149. Travoprost - 0.004%;
150. Bimatoprost - 0.03%;
151. Latanoprost - 0.005%;
152. Travoprost - 0.004%;
153. Bimatoprost - 0.03%;
154. Latanoprost - 0.005%;
155. Travoprost - 0.004%;
156. Bimatoprost - 0.03%;
157. Latanoprost - 0.005%;
158. Travoprost - 0.004%;
159. Bimatoprost - 0.03%;
160. Latanoprost - 0.005%;
161. Travoprost - 0.004%;
162. Bimatoprost - 0.03%;
163. Latanoprost - 0.005%;
164. Travoprost - 0.004%;
165. Bimatoprost - 0.03%;
166. Latanoprost - 0.005%;
167. Travoprost - 0.004%;
168. Bimatoprost - 0.03%;
169. Latanoprost - 0.005%;
170. Travoprost - 0.004%;
171. Bimatoprost - 0.03%;
172. Latanoprost - 0.005%;
173. Travoprost - 0.004%;
174. Bimatoprost - 0.03%;
175. Latanoprost - 0.005%;
176. Travoprost - 0.004%;
177. Bimatoprost - 0.03%;
178. Latanoprost - 0.005%;
179. Travoprost - 0.004%;
180. Bimatoprost - 0.03%;
181. Latanoprost - 0.005%;
182. Travoprost - 0.004%;
183. Bimatoprost - 0.03%;
184. Latanoprost - 0.005%;
185. Travoprost - 0.004%;
186. Bimatoprost - 0.03%;
187. Latanoprost - 0.005%;
188. Travoprost - 0.004%;
189. Bimatoprost - 0.03%;
190. Latanoprost - 0.005%;
191. Travoprost - 0.004%;
192. Bimatoprost - 0.03%;
193. Latanoprost - 0.005%;
194. Travoprost - 0.004%;
195. Bimatoprost - 0.03%;
196. Latanoprost - 0.005%;
197. Travoprost - 0.004%;
198. Bimatoprost - 0.03%;
199. Latanoprost - 0.005%;
200. Travoprost - 0.004%;
201. Bimatoprost - 0.03%;
202. Latanoprost - 0.005%;
203. Travoprost - 0.004%;
204. Bimatoprost - 0.03%;
205. Latanoprost - 0.005%;
206. Travoprost - 0.004%;
207. Bimatoprost - 0.03%;
208. Latanoprost - 0.005%;
209. Travoprost - 0.004%;
210. Bimatoprost - 0.03%;
211. Latanoprost - 0.005%;
212. Travoprost - 0.004%;
213. Bimatoprost - 0.03%;
214. Latanoprost - 0.005%;
215. Travoprost - 0.004%;
216. Bimatoprost - 0.03%;
217. Latanoprost - 0.005%;
218. Travoprost - 0.004%;
219. Bimatoprost - 0.03%;
220. Latanoprost - 0.005%;
221. Travoprost - 0.004%;
222. Bimatoprost - 0.03%;
223. Latanoprost - 0.005%;
224. Travoprost - 0.004%;
225. Bimatoprost - 0.03%;
226. Latanoprost - 0.005%;
227. Travoprost - 0.004%;
228. Bimatoprost - 0.03%;
229. Latanoprost - 0.005%;
230. Travoprost - 0.004%;
231. Bimatoprost - 0.03%;
232. Latanoprost - 0.005%;
233. Travoprost - 0.004%;
234. Bimatoprost - 0.03%;
235. Latanoprost - 0.005%;
236. Travoprost - 0.004%;
237. Bimatoprost - 0.03%;
238. Latanoprost - 0.005%;
239. Travoprost - 0.004%;
240. Bimatoprost - 0.03%;
241. Latanoprost - 0.005%;
242. Travoprost - 0.004%;
243. Bimatoprost - 0.03%;
244. Latanoprost - 0.005%;
245. Travoprost - 0.004%;
246. Bimatoprost - 0.03%;
247. Latanoprost - 0.005%;
248. Travoprost - 0.004%;
249. Bimatoprost - 0.03%;
250. Latanoprost - 0.005%;
251. Travoprost - 0.004%;
252. Bimatoprost - 0.03%;
253. Latanoprost - 0.005%;
254. Travoprost - 0.004%;
255. Bimatoprost - 0.03%;
256. Latanoprost - 0.005%;
257. Travoprost - 0.004%;
258. Bimatoprost - 0.03%;
259. Latanoprost - 0.005%;
260. Travoprost - 0.004%;
261. Bimatoprost - 0.03%;
262. Latanoprost - 0.005%;
263. Travoprost - 0.004%;
264. Bimatoprost - 0.03%;
265. Latanoprost - 0.005%;
266. Travoprost - 0.004%;
267. Bimatoprost - 0.03%;
268. Latanoprost - 0.005%;
269. Travoprost - 0.004%;
270. Bimatoprost - 0.03%;
271. Latanoprost - 0.005%;
272. Travoprost - 0.004%;
273. Bimatoprost - 0.03%;
274. Latanoprost - 0.005%;
275. Travoprost - 0.004%;
276. Bimatoprost - 0.03%;
277. Latanoprost - 0.005%;
278. Travoprost - 0.004%;
279. Bimatoprost - 0.03%;
280. Latanoprost - 0.005%;
281. Travoprost - 0.004%;
282. Bimatoprost - 0.03%;
283. Latanoprost - 0.005%;
284. Travoprost - 0.004%;
285. Bimatoprost - 0.03%;
286. Latanoprost - 0.005%;
287. Travoprost - 0.004%;
288. Bimatoprost - 0.03%;
289. Latanoprost - 0.005%;
290. Travoprost - 0.004%;
291. Bimatoprost - 0.03%;
292. Latanoprost - 0.005%;
293. Travoprost - 0.004%;
294. Bimatoprost - 0.03%;
295. Latanoprost - 0.005%;
296. Travoprost - 0.004%;
297. Bimatoprost - 0.03%;
298. Latanoprost - 0.005%;
299. Travoprost - 0.004%;
300. Bimatoprost - 0.03%;
301. Latanoprost - 0.005%;
302. Travoprost - 0.004%;
303. Bimatoprost - 0.03%;
304. Latanoprost - 0.005%;
305. Travoprost - 0.004%;
306. Bimatoprost - 0.03%;
307. Latanoprost - 0.005%;
308. Travoprost - 0.004%;
309. Bimatoprost - 0.03%;
310. Latanoprost - 0.005%;
311. Travoprost - 0.004%;
312. Bimatoprost - 0.03%;
313. Latanoprost - 0.005%;
314. Travoprost - 0.004%;
315. Bimatoprost - 0.03%;
316. Latanoprost - 0.005%;
317. Travoprost - 0.004%;
318. Bimatoprost - 0.03%;
319. Latanoprost - 0.005%;
320. Travoprost - 0.004%;
321. Bimatoprost - 0.03%;
322. Latanoprost - 0.005%;
323. Travoprost - 0.004%;
324. Bimatoprost - 0.03%;
325. Latanoprost - 0.005%;
326. Travoprost - 0.004%;
327. Bimatoprost - 0.03%;
328. Latanoprost - 0.005%;
329. Travoprost - 0.004%;
330. Bimatoprost - 0.03%;
331. Latanoprost - 0.005%;
332. Travoprost - 0.004%;
333. Bimatoprost - 0.03%;
334. Latanoprost - 0.005%;
335. Travoprost - 0.004%;
336. Bimatoprost - 0.03%;
337. Latanoprost - 0.005%;
338. Travoprost - 0.004%;
339. Bimatoprost - 0.03%;
340. Latanoprost - 0.005%;
341. Travoprost - 0.004%;
342. Bimatoprost - 0.03%;
343. Latanoprost - 0.005%;
344. Travoprost - 0.004%;
345. Bimatoprost - 0.03%;
346. Latanoprost - 0.005%;
347. Travoprost - 0.004%;
348. Bimatoprost - 0.03%;
349. Latanoprost - 0.005%;
350. Travoprost - 0.004%;
351. Bimatoprost - 0.03%;
352. Latanoprost - 0.005%;
353. Travoprost - 0.004%;
354. Bimatoprost - 0.03%;
355. Latanoprost - 0.005%;
356. Travoprost - 0.004%;
357. Bimatoprost - 0.03%;
358. Latanoprost - 0.005%;
359. Travoprost - 0.004%;
360. Bimatoprost - 0.03%;
361. Latanoprost - 0.005%;
362. Travoprost - 0.004%;
363. Bimatoprost - 0.03%;
364. Latanoprost - 0.005%;
365. Travoprost - 0.004%;
366. Bimatoprost - 0.03%;
367. Latanoprost - 0.005%;
368. Travoprost - 0.004%;
369. Bimatoprost - 0.03%;
370. Latanoprost - 0.005%;
371. Travoprost - 0.004%;
372. Bimatoprost - 0.03%;
373. Latanoprost - 0.005%;
374. Travoprost - 0.004%;
375. Bimatoprost - 0.03%;
376. Latanoprost - 0.005%;
377. Travoprost - 0.004%;
378. Bimatoprost - 0.03%;
379. Latanoprost - 0.005%;
380. Travoprost - 0.004%;
381. Bimatoprost - 0.03%;
382. Latanoprost - 0.005%;
383. Travoprost - 0.004%;
384. Bimatoprost - 0.03%;
385. Latanoprost - 0.005%;
386. Travoprost - 0.004%;
387. Bimatoprost - 0.03%;
388. Latanoprost - 0.005%;
389. Travoprost - 0.004%;
390. Bimatoprost - 0.03%;
391. Latanoprost - 0.005%;
392. Travoprost - 0.004%;
393. Bimatoprost - 0.03%;
394. Latanoprost - 0.005%;
395. Travoprost - 0.004%;
396. Bimatoprost - 0.03%;
397. Latanoprost - 0.005%;
398. Travoprost - 0.004%;
399. Bimatoprost - 0.03%;
400. Latanoprost - 0.005%;
401. Travoprost - 0.004%;
402. Bimatoprost - 0.03%;
403. Latanoprost - 0.005%;
404. Travoprost - 0.004%;
405. Bimatoprost - 0.03%;
406. Latanoprost - 0.005%;
407. Travoprost - 0.004%;
408. Bimatoprost - 0.03%;
409. Latanoprost - 0.005%;
410. Travoprost - 0.004%;
411. Bimatoprost - 0.03%;
412. Latanoprost - 0.005%;
413. Travoprost - 0.004%;
414. Bimatoprost - 0.03%;
415. Latanoprost - 0.005%;
416. Travoprost - 0.004%;
417. Bimatoprost - 0.03%;
418. Latanoprost - 0.005%;
419. Travoprost - 0.004%;
420. Bimatoprost - 0.03%;
421. Latanoprost - 0.005%;
422. Travoprost - 0.004%;
423. Bimatoprost - 0.03%;
424. Latanoprost - 0.005%;
425. Travoprost - 0.004%;
426. Bimatoprost - 0.03%;
427. Latanoprost - 0.005%;
428. Travoprost - 0.004%;
429. Bimatoprost - 0.03%;
430. Latanoprost - 0.005%;
431. Travoprost - 0.004%;
432. Bimatoprost - 0.03%;
433. Latanoprost - 0.005%;
434. Travoprost - 0.004%;
435. Bimatoprost - 0.03%;
436. Latanoprost - 0.005%;
437. Travoprost - 0.004%;
438. Bimatoprost - 0.03%;
439. Latanoprost - 0.005%;
440. Travoprost - 0.004%;
441. Bimatoprost - 0.03%;
442. Latanoprost - 0.005%;
443. Travoprost - 0.004%;
444. Bimatoprost - 0.03%;
445. Latanoprost - 0.005%;
446. Travoprost - 0.004%;
447. Bimatoprost - 0.03%;
448. Latanoprost - 0.005%;
449. Travoprost - 0.004%;
450. Bimatoprost - 0.03%;
451. Latanoprost - 0.005%;
452. Travoprost - 0.004%;
453. Bimatoprost - 0.03%;
454. Latanoprost - 0.005%;
455. Travoprost - 0.004%;
456. Bimatoprost - 0.03%;
457. Latanoprost - 0.005%;
458. Travoprost - 0.004%;
459. Bimatoprost - 0.03%;
460. Latanoprost - 0.005%;
461. Travoprost - 0.004%;
462. Bimatoprost - 0.03%;
463. Latanoprost - 0.005%;
464. Travoprost - 0.004%;
465. Bimatoprost - 0.03%;
466. Latanoprost - 0.005%;
467. Travoprost - 0.004%;
468. Bimatoprost - 0.03%;
469. Latanoprost - 0.005%;
470. Travoprost - 0.004%;
471. Bimatoprost - 0.03%;
472. Latanoprost - 0.005%;
473. Travoprost - 0.004%;
474. Bimatoprost - 0.03%;
475. Latanoprost - 0.005%;
476. Travoprost - 0.004%;
477. Bimatoprost - 0.03%;
478. Latanoprost - 0.005%;
479. Travoprost - 0.004%;
480. Bimatoprost - 0.03%;
481. Latanoprost - 0.005%;
482. Travoprost - 0.004%;
483. Bimatoprost - 0.03%;
484. Latanoprost - 0.005%;
485. Travoprost - 0.004%;
486. Bimatoprost - 0.03%;
487. Latanoprost - 0.005%;
488. Travoprost - 0.004%;
489. Bimatoprost - 0.03%;
490. Latanoprost - 0.005%;
491. Travoprost - 0.004%;
492. Bimatoprost - 0.03%;
493. Latanoprost - 0.005%;
494. Travoprost - 0.004%;
495. Bimatoprost - 0.03%;
496. Latanoprost - 0.005%;
497. Travoprost - 0.004%;
498. Bimatoprost - 0.03%;
499. Latanoprost - 0.005%;
500. Travoprost - 0.004%;
501. Bimatoprost - 0.03%;
502. Latanoprost - 0.005%;
503. Travoprost - 0.004%;
504. Bimatoprost - 0.03%;
505. Latanoprost - 0.005%;
506. Travoprost - 0.004%;
507. Bimatoprost - 0.03%;
508. Latanoprost - 0.005%;
509. Travoprost - 0.004%;
510. Bimatoprost - 0.03%;
511. Latanoprost - 0.005%;
512. Travoprost - 0.004%;
513. Bimatoprost - 0.03%;
514. Latanoprost - 0.005%;
515. Travoprost - 0.004%;
516. Bimatoprost - 0.03%;
517. Latanoprost - 0.005%;
518. Travoprost - 0.004%;
519. Bimatoprost - 0.03%;
520. Latanoprost - 0.005%;
521. Travoprost - 0.004%;
522. Bimatoprost - 0.03%;</

Home Licensing Renewals Resources Meetings The Board

Important Information Regarding Rhopressa

Click here to find out more about Rule 64B13-18.002 formulary of Topical Ocular Pharmaceutical Agents, Rhopressa (netarsudil ophthalmic solution) 0.02%.)

(d) Alpha, Adrenergic Agonist
 1. Brimonidine tartrate – 0.15%, 0.2%; and,
 2. Apraclonidine HCl – 0.5%.

(e) Carbonic Anhydrase Inhibitors (CAI's)
 1. Brinzolamide – 1.0%; and,
 2. Dorzolamide HCl – 2.0% (alone and in combination).

(f) **Rho Kinase Inhibitor – Netarsudil – 0.02%;**

OptometricEdu.com/Webinars

Home Licensing Renewals Resources Meetings The Board

Important Information Regarding Cequa

During the September 26, 2018 Board of Optometry meeting, the board approved for addition to the Formulary of Topical Ocular Pharmaceutical Agents the ophthalmic solution Cequa.

(9) MISCELLANEOUS
 (a) Hydroxypropyl cellulose ophthalmic Insert;
 (b) Dapiprazole – 0.5%;
 (c) Cyclosporine emulsion – 0.05%;
 (d) Polyvinyl pyrrolidone – drops 2.0%;
 (e) Bimatoprost – .03%;
 (f) Natamycin Ophthalmic Suspension 5%;
 (g) Lifitegrast ophthalmic solution 5%; and,
 (h) **Cyclosporine 0.09% Ophthalmic Solution.**

OptometricEdu.com/Webinars

Home Licensing Renewals Resources Meetings The Board

Important Information Regarding Rhopressa

Click here to find out more about Rule 64B13-18.002 formulary of Topical Ocular Pharmaceutical Agents, Rhopressa (netarsudil ophthalmic solution) 0.02%.)

FDA Approves Rocklatan Eye Drop for Open-angle Glaucoma

Aerie Pharmaceuticals announced that the FDA has approved Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension.

The Board of Optometry met on July 18, 2019 in Orlando regarding adding Rocklatan to the formulary; the board dismissed the request as name-brands cannot be added, and the combined ingredients are already on the formulary.

OptometricEdu.com/Web

FLORIDA Board of Optometry

Search Posts, Pages & FAQs

FAQs Contact Us Sign Up

Thursday, September 26th, 2019

Home Licensing Renewals Resources Meetings The Board

Brand Names not allowed on formulary.

The Board of Optometry met on July 18, 2019 in Orlando regarding adding Rocklatan to the formulary. Click here for more information on the formulary.

Welcome to the State of Florida's Online Resource for Optometrists and Faculty Certificate Holders
 Licensing, Renewals and Information

FLORIDA Board of Optometry

Search Posts, Pages & FAQs

FAQs Contact Us Sign Up

Thursday, September 26th, 2019

Home Licensing Renewals Resources Meetings The Board

Important notice regarding Intelys

The board approved Intelys (atropine/edrophonium ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, licensees are now permitted to prescribe Intelys.

Welcome to the State of Florida's Online Resource for Optometrists and Faculty Certificate Holders
 Licensing, Renewals and Information

Proposed bill to remove period of notification and match FDA approval

FLORIDA Board of Optometry

Search Posts, Pages & FAQs

FAQs Contact Us Sign Up

Thursday, September 26th, 2019

Home Licensing Renewals Resources Meetings The Board

Minors

When a patient is under the age of 18, the parent or legal guardian must provide written consent for the patient to receive any services, including but not limited to, the following:

- Issuing the prescription provided to the patient by the parent.
- Authorizing health care practitioners to discuss non-optical examinations with, and provide the prescription to, the patient's representative rather than the patient.
- Specifying that any health care practitioner reviewing or providing a prescription must sign the prescription and the date of the examination or examination date must be on the prescription and the date of the examination or examination date must be on the prescription.
- Issuing the prescription and providing the prescription to the parent or legal guardian and providing the parent or legal guardian with a copy of the parent's representative and provide a printed copy of the prescription.

Talk to your health care provider about how to treat your pain. Create a safe and effective treatment plan that is right for you.

Alternatives to Opioids: Medications

Alternatives to Opioids: Therapies

Alternatives to Opioids: Medications

Alternatives to Opioids: Therapies

FLORIDA Board of Optometry

Search Page, Pages & FAQs

FAQs Contact Sign up

Thursday, September 26th, 2019

Home Licensing Renewals Resources Meetings The Board

HUMAN TRAFFICKING

Human Trafficking

Click here for new profession requirements and reporting procedures regarding Human Trafficking

Welcome to the State of Florida's Online Resource for Optometrists and Faculty Certificate Holders

Licensing, Renewals and Information

FLORIDA Board of Optometry

Search Page, Pages & FAQs

FAQs Contact Sign up

Thursday, September 26th, 2019

Home Licensing Renewals Resources Meetings The Board

Human Trafficking

Posted in Latest News on July 27, 2019.

Florida passed Human Trafficking, Chapter 2019-152, Laws of Florida, which establishes new profession requirements including newly required signs, CE/CME, and more for the following professions: Acupuncture, Medicine, Osteopathic Medicine, Chiropractic Medicine, Podiatric Medicine, Optometry, Pharmacy, Dentistry, Nursing Home Administration, Occupational Therapy, Dietetics and Nutrition, Respiratory Care, Massage Therapy, and Physical Therapy.

The Department has launched an informational website that includes a breakdown of the new law and addresses areas of: (1) signs; (2) CE/CME; (3) FAQs; (4) Specific Board of Massage requirements; and (5) Human Trafficking Reporting.

For more information please visit: <http://www.floridaboardsofhealthcare.com/humantrafficking/>

Apply Renew Status Lookup Complaints

SIGNS

Each healthcare provider licensed by one of the named Boards must post a sign regarding human trafficking in a conspicuous place accessible to employees by January 1, 2021. The sign must be at least 11 x 15 inches and in at least 32-point type. The sign must contain statutorily required language and be posted in English and Spanish. The Department has also provided Mandarin translations of these signs for use in offices where those languages are spoken. The links below contain signs that meet the statutory requirements when printed at the listed size.

- Human Trafficking (English/Spanish)
- Human Trafficking (English/Spanish/Mandarin)

If you or someone you know is being forced to engage in an activity and cannot leave,

whether it is prostitution, housework, farm work, factory work, retail work, restaurant work, or any other activity, call the National Human Trafficking Resource Center at **888-373-7888** or text **INFO** or **HELP** to **233-733** to access help and services. Victims of slavery and human trafficking are protected under United States and Florida law.

HOME SIGNS CE/CME MESSAGE FAQ FIND HELP

CE


Each healthcare provider licensed by one of the named Boards must complete a new hour continuing education (CE) course on human trafficking that has been specifically approved by their Board for this purpose. The course must be completed by January 1, 2021 and will count towards the required CE for renewal. The bill does not require that this course be taken again for future renewal cycles. The links below will direct you to courses that meet this requirement as soon as they are approved by the applicable Board.

To find an appropriate course, please visit:

- January 1, 2021
- 1 hr; Once only; Counts towards 30 hrs
- Live or online

All right...let's talk about CE

- 30 hours each biennium ending on last day of February of odd years to include the following:
 - 6 hours TQ
 - 2 hours Florida Jurisprudence (live)
 - 2 hours Prevention of Medical Errors
 - 1-hour HIV/AIDS (prevention/ transmission, NOT ocular manifestations) for first license renewal only
 - 1-hour Human Trafficking 2021
- *Online is allowed 12/1/20-2/28/21. FL Surgeon General extended renewal to 3/31/21. 3/1/21-3/31/21 must be live. March can apply to either biennium*
- **Exceptions:**
 - 20-hour oral course (but doesn't count as TQ even with exam)
 - Human trafficking
 - 2 hours practice management
 - 2 hours opioids (must take if DEA, may take for general hours)




Who here uses EHR?

House Bill 831 (2019), Electronic Prescribing, was signed into law by Governor DeSantis. The effective date is January 1, 2020. The bill provides important new requirements for prescribers to generate and transmit all prescriptions electronically upon licensure renewal or by July 1, 2021, whichever is earlier.

The law requires prescribers to generate and transmit all prescription electronically, unless:

- The practitioner and the dispenser are the same entity;
- The prescription cannot be transmitted electronically under the most recently implemented version of the National Council for Prescription Drug Programs SCRIPT Standard;
- The practitioner has been issued a waiver by the department, not to exceed 1 year, due to demonstrated economic hardship, technology limitations that are not reasonably within the control of the practitioner, or another exceptional circumstance demonstrated by the practitioners;
- The practitioner reasonably determines that it would be impractical for the patient in question to obtain a medicinal drug prescribed by electronic prescription in a timely manner and such delay would adversely impact the patient's medical condition;

- The practitioner is prescribing a drug under a research protocol;
- The prescription is for a drug for which the federal Food and Drug Administration requires the prescription to contain elements that may not be included in electronic prescribing;
- The prescription is issued to an individual receiving hospice care or who is a resident of a nursing home facility; or
- The practitioner determines that it is in the best interest of the patient, or the patient determines that it is in his or her own best interest to compare prescription drug prices among area pharmacies. The practitioner must document such determination in the patient's medical record.



463.0141 Reports of adverse incidents in the practice of optometry

- Effective January 1, 2014, an adverse incident occurring in the practice of optometry must be reported to the Department of Health
- "Adverse incident" is specifically defined in subsection 463.0141 (3) to mean any of the following events when it is reasonable to believe that the event is attributable to the prescription of an **ORAL** ocular pharmaceutical agent by the optometrist.

HB 239

463.0141 Reports of adverse incidents in the practice of optometry

- Any condition that requires transfer of the patient to a licensed hospital;
- Any condition that requires the patient to obtain care from a medical doctor or osteopathic doctor, other than a referral or a consultation required by Chapter 463;
- Permanent physical injury to the patient;
- Partial or complete permanent loss of sight by the patient; or
- Death of the patient.

HB 239

463.0141 Reports of adverse incidents in the practice of optometry

- If an "adverse incident" defined in subsection 463.0141 (3) occurs, the optometrist is required to provide written notice to the Florida Department of Health by certified mail.
- If the incident takes place while the patient is in the optometrist's office, the notice must be postmarked within 15 days after occurrence.
- If the incident occurs when the patient is not at the optometrist's office, the notification must be postmarked within 15 days after the optometrist discovers, or reasonably should have discovered, the occurrence of the adverse incident

Controlled Substances

- To secure DOH approval, the counterfeit-proof pad or blank must contain certain security features [i.e., must be blue or green, printed on artificial watermarked paper, must resist erasures and alterations, and "void" or "illegal" must appear on any photocopy or other reproduction of the pad or blank]; and
- To secure DOH approval, the counterfeit-proof pad or blank must also contain the preprinted name, address and category of professional licensure, or a space for the prescriber's name if not preprinted, and a space for the practitioner's DEA registration number.

Controlled Substances

- Tylenol w/Codeine - Acetaminophen 300 mg with No. 3 codeine phosphate 30 mg.
 - Only for eye conditions.
 - Cannot be used for Chronic or nonmalignant pain
 - "Chronic nonmalignant pain" means pain unrelated to cancer which persists beyond the usual course of disease or the injury that is the cause of the pain or more than 90 days after surgery.

Analgesics

- Tramadol hydrochloride
 - may not be administered or prescribed for more than 72 hours without consultation with a physician licensed under chapter 458 or chapter 459 who is skilled in diseases of the eye:

Controlled Substances

- Florida Statutes, provides that a written prescription for a controlled substance listed in chapter 893 must be either written on a standardized counterfeit-proof prescription pad produced by a vendor approved by the Florida Department of Health (DOH) or electronically prescribed

Controlled Substances

- Section 893.04 provides that a pharmacy may dispense a prescribed controlled substance only if the **full name and address of the prescribing practitioner and the practitioner's DEA registration number is printed thereon.**

Controlled Substances

- DEA Numbers
 - Applications submitted at <http://www.deadiversion.usdoj.gov/drugreg/>
 - \$731 every 3 years
- 2 Controlled Substances - Schedule 3
 - A certified optometrist licensed under chapter 463 may not administer or prescribe a controlled substance listed in Schedule I or Schedule II of s. 893.03.
- Tylenol w/Codeine - Acetaminophen 300 mg with No. 3 codeine phosphate 30 mg.
- Tramadol hydrochloride

Antibiotics

- The following antibiotics or their generic or therapeutic equivalents:
 - Amoxicillin with or without clavulanic acid.
 - Azithromycin.
 - Erythromycin.
 - Dicloxacillin.
 - Doxycycline/Tetracycline.
 - Keflex
 - Minocycline

Antiviral

- The following antivirals or their generic or therapeutic equivalents:
 - Acyclovir
 - Famciclovir
 - Valacyclovir

Anti-Glaucoma

- The following oral anti-glaucoma agents or their generic or therapeutic equivalents, which may not be administered or prescribed for more than 72 hours:
 - Acetazolamide
 - Methazolamide

463.014 Certain acts prohibited

- (3) Prescribing, ordering, dispensing, administering, supplying, selling, or giving any drug for the purpose of treating a systemic disease by a licensed practitioner is prohibited. **However, a certified optometrist is permitted to use commonly accepted means or methods to immediately address incidents of anaphylaxis.**

EpiPEN® for Anaphylaxis

- EpiPen® 0.3 mg
 - **Yellow** label - 66 lbs or more
- EpiPen® Jr. 0.15 mg
 - **Green** label - 33-66 lbs.



Florida Optometry Oral Drug Review Course & Examination
Certified Optometrists: Complete This Course and Issue Oral Ocular Prescriptions
20-Hour Florida Optometry Board-Approved 100% Online Course

- Complete Your Optometrist Continuing Ed Requirement
- Learn Dispensing Rules & Essential Application Information
- Provided through the Florida Medical Association
- Florida Certified Optometrists-Specific for Prescription of Oral Ocular Pharmaceutical Agents
- Meets Florida Optometry Oral Drug Law Requirements (Chapter 2013 JLS, Laws of Florida)

Course Fee: \$995 **REGISTER NOW!**

Copyright © 2022, American Academy of Optometry, Inc. All Rights Reserved.
Privacy & Confidentiality | Intellectual Property | Webmaster: Optometric

OptometricEdu.com/Webinars

Declaratory Statement

Prokera®

The Florida Board of Optometry recently issued a declaratory statement finding that the non-surgical application of Prokera® [described by CPT code 65778 as the placement of amniotic membrane on the ocular surface without the use of sutures] by a Florida certified optometrist is authorized as being within the scope of optometric practice in Florida.

OptometricEdu.com/Webinars

FLORIDA Board of Optometry

Home Licensing Renewals Resources Meetings The Board

Florida Jurisprudence CE Requirement

Posted in [Legal News](#) on February 22, 2023

If you are an out-of-state licensee affected by Rule 64B13-002, and are not practicing in Florida, your CE transcript in CE Broker shall be updated momentarily.

During each subsequent renewal, you will be required to complete the 2-hour Florida Jurisprudence course. If you should have any problems with renewing your license, please contact our Customer Contact Center at 850-488-0795.

[Previous Post](#) [Next Post](#)

- Apply for a License
- Renew a License
- Status
- Lookup
- Complaints

OptometricEdu.com/Webinars

It's a good thing you're here!

Course must be live, no more affidavit

- (6) As part of the thirty (30) clock hours, licensed practitioners shall be required to obtain **two (2) hours in the area of Florida jurisprudence**.
- (a) No more than two (2) hours of continuing education in the area of Florida jurisprudence may be applied to the thirty (30) clock hour requirement in subsection (1).
- (b) A licensed practitioner may earn two (2) hours in Florida jurisprudence by **attending a meeting of the Board at which another licensee is disciplined for no less than four (4) continuous hours**. Licensed practitioners will be required to sign-in and sign-out with board staff. Those licensed practitioners present for disciplinary purposes are not eligible to earn the two (2) clock hours for the Board meeting.

DO NOT send in a signed affidavit stating that you read the laws and rules after October 2, 2018

OptometricEdu.com/Webinars

Next Meeting:
May 12, 2023
Board of Optometry

Meeting Location:
Telephone Conference Call @ 900am ET
[GoToMeeting Link](#)

Meeting Materials:
[FAR Notice \(PDF\)](#)

463.0135 Standards of practice

- A licensed practitioner shall provide that degree of care which conforms to that level of care provided by medical practitioners in the same or similar communities. A licensed practitioner shall advise or assist her or his patient in obtaining further care when the service of another health care practitioner is required

OptometricEdu.com/Webinars

Standards of practice

• 64813-2.008 Probable Cause Panel.

- (1) The determination as to whether probable cause exists to believe that a violation of the provisions of Chapter 456, Part II, or 463, F.S., or of the rules promulgated thereunder, has occurred shall be made by the probable cause panel of the Board.
- (2) The probable cause panel shall be composed of at least two (2) present or former members of the Board of Optometry. At least one member of the panel must be a current Board member. At least one member shall be a present or former lay member, if available, willing to serve, and authorized by the Chair.

456

In determining what action is appropriate, the board, or department when there is no board, must first consider what sanctions are necessary to protect the public or to **compensate the patient**. Only after those sanctions have been imposed may the disciplining authority consider and include in the order requirements designed to rehabilitate the practitioner. **All costs** associated with compliance with orders issued under this subsection **are the obligation of the practitioner**.

What does this mean to you?

- When in doubt, give the money back to the patient (within reason).
 - Leading complaint to Board: failure to refund money for glasses
 - Could then lead to investigation into file
 - Take care Board doesn't overstep authority
- If a grievance is filed, you must defend yourself, preferably with the assistance of an attorney.
- Malpractice insurance typically does not cover this. You must bear the costs personally. Check with carrier now

Minimum Equipment

The following shall constitute the minimum equipment which a licensed practitioner must possess in each office in which he or she engages in the practice of optometry:

- (1) Ophthalmoscope;
- (2) Tonometer;
- (3) Retinoscope;
- (4) Ophthalmometer, keratometer or corneal topographer;

Minimum Equipment

- (5) Biomicroscope;
- (6) Phoropter or trial frame, trial lenses and prisms;
- (7) Standard charts or other standard visual acuity test;
- (8) Field testing equipment (other than that used for a confrontation test).

Note: Pachymeter, fundus camera, OCT, etc., not part of the minimum

Minimum Exam

64813-3.007 Minimum Procedures for Vision Analysis (comprehensive eye exam).

- (1) Vision analysis is defined as a comprehensive assessment of the patient's visual status and shall include those procedures specified in subsection (2) below.
- (2) An examination for vision analysis shall include the following minimum procedures, which shall be recorded on the patient's case record:
 - (a) Patient's history (personal and family medical history, personal and family ocular history, and chief complaint);

Minimum Exam

- (b) Visual acuity (unaided and with present correction at initial presentation; thereafter, unaided or with present correction);
- (c) External examination;
- (d) Pupillary examination;
- (e) Visual field testing (confrontation or other);
- (f) Internal examination (direct or indirect ophthalmoscopy recording cup disc ratio, blood vessel status and any abnormalities);

Minimum Exam

- (g) Biomicroscopy (binocular or monocular);
- (h) Tonometry;
- (i) Refraction (with recorded visual acuity);
- (j) Extra ocular muscle balance assessment;

Minimum Exam

- (k) Other tests and procedures that may be indicated by case history or objective signs and symptoms discovered during the eye examination;
- (l) Diagnosis and treatment plan.
- (3) If because of the patient's age or physical limitations, one or more of the procedures specified herein or any part thereof, cannot be performed, or if the procedures or any part thereof are to be performed by reason of exemption from this rule, the reason or exemption shall be noted on the patient's case record.

Minimum Exam

- Except as otherwise provided in this rule, the minimum procedures set forth in subsection (2) above shall be performed prior to providing optometric care during a patient's initial presentation, and thereafter at such appropriate intervals as shall be determined by the **optometrist's sound professional judgment**. Provided, however, that each optometric patient shall receive a complete vision analysis prior to the provision of further optometric care if the last complete vision analysis was performed more than two years before.

So what does this mean to you?

- Subjective:
 - personal and family medical history, personal and family ocular history, and chief complaint
- Objective:
 - VA (with and without at initial; with afterwards); pupils, EOMs, screening fields (*confrontation*), ocular balance (Cover test), refraction, SLE, tonometry (some method), fundus (dilation at first-disc, vessels, abnormalities), any and all others as dictated by exam
- Assessment- detailed
- Plan-detailed

Standards of Practice

- (7)(a) To be in compliance with paragraph 64813-3.007(2)(f), F.A.C., certified optometrists shall perform a **dilated fundus examination** during the patient's initial presentation, and thereafter, whenever medically indicated. If, in the certified optometrist's sound professional judgment, dilation is not performed because of the patient's age, physical limitations, or conditions, the **reason(s) shall be noted in the patient's medical record**.
- (b) **Licensed optometrists** who determine that a dilated fundus examination is medically indicated shall advise the patient that such examination is medically necessary and shall refer the patient to a qualified health care professional for such examination to be performed. The licensed optometrist shall document the advice and referral in the patient's medical record.

Imaging of the fundus does not count.

What about non-Comprehensive exams?

- Whenever a patient presents to a licensed practitioner or certified optometrist with any of the following as the primary complaint, the performance of the minimum procedures set forth in subsection (2) above shall not be required.
 - (a) Emergencies;
 - (b) Trauma;
 - (c) Infectious disease;
 - (d) Allergies;
 - (e) Toxicities; or
 - (f) Inflammations.

- The minimum procedures set forth in subsection (2) above shall not be required in the following circumstances:
- (a) When a licensed practitioner or certified optometrist is providing specific optometric services on a secondary or tertiary basis in patient co-management with one or more health care practitioners skilled in the diagnosis and treatment of diseases of the human eye and licensed pursuant to Chapter 458, 459, or 463, Florida Statutes

So what does this mean to you?

- If you can't do a required test, state the reason and the attempt.
- Reason for this statute is to protect and provide to public quality care
 - Discourages 'refraction mills'
 - "There is no reason that you cannot do an eye exam in less than 5 minutes"

Branch License

- 2014- you no longer need to apply for branch licenses for each office
- You must however have a copy of your Florida license displayed in each office



Dispensing Optometrists

Florida Statutes, Section 463.0055, permits certified optometrists to administer and prescribe ocular pharmaceutical agents for the diagnosis and treatment of ocular conditions of the eye and its appendages.

Florida Statutes, Section 465.0276, permits registered practitioners authorized by law to prescribe drugs, including optometrists, to dispense such drugs to their patients in the regular course of their practice. This means that optometrists, as part of their practice, are allowed to sell the drugs they are permitted by law to prescribe. However, optometrists may not dispense any controlled substance listed in Schedule II or Schedule III, as provided in Florida Statutes, Section 893.03.

Drug Dispensing- For Profit

- A certified optometrist who dispenses medicinal drugs for a fee must register as a dispensing practitioner with the Florida Board of Optometry and pay a fee of \$100.00 at the time of registration and upon each biennial renewal of licensure.
- Subject to and must comply with all laws and rules applicable to pharmacists and pharmacies
- Department of Health is authorized to inspect in the same manner and same frequency as it inspects pharmacies

Drug Dispensing- Samples

- Not required to register as a dispensing practitioner
- Must dispense the medicinal drugs in the manufacturer's labeled package with the practitioner's name, patient's name, and date dispensed.
- If not dispensed in the manufacturer's labeled package, they must bear the following information:
 - Practitioner's name;
 - Patient's name;
 - Date dispensed;
 - Name and strength of drug; and
 - Directions for use.

What can get you sued for malpractice and what can get you sanctioned by the Board of Optometry are often two different things

The Board of Optometry does not involve itself in malpractice suits. Getting sued for malpractice does not get reported to the Board. The patient or other entity must file a separate grievance with the Board.

Bad Outcome vs Malpractice

- Florida OD
- 60 YOBF
- Routine exam
- IOP: Upper 40's OU
- Glaucoma suspect
- Begins topical treatment
- Manages for 2 years
- IOP low to mid 20's

Bad Outcome vs Malpractice

- Seeks care from ophthalmologist
- On multiple meds
- IOP mid 20's
- Meds changed
- IOP low 20's
- Undergoes ALTP, then trabeculectomy OU
- Sues optometrist
- Retained by patient's attorney

Bad Outcome vs Malpractice

- Allegations:
 - Detected elevated IOP and only used topical medications
 - Diagnosed glaucoma, but failed to warn of serious nature
 - Failed to diagnose optic nerve injury
 - Failed to properly treat optic nerve injury
 - Failed to refer to ophthalmologist

**CONSENT TO PROVIDE HEALTH CARE SERVICES TO
MINOR CHILD**

I, _____ (parent or legal guardian), give written consent to _____ to arrange, schedule, and/or provide health care services, including the administration of topical anesthetics and prescription of medicinal drugs, to _____ (minor child), as deemed necessary for the health and welfare of said minor child. This authorization is effective from the date of signature.

Minor Child's Name: _____ DOB: _____

Signature of Parent or Legal Guardian: _____ Date: _____

Relationship to Child: _____

Known Drug Allergies: _____

Current Medications: _____

Primary Care Physician: _____

**What happens when you
get in trouble with the
Board?**

Case: Running afoul of a crazy person

- Visit 1: Older female presents for CEE
 - checks off on a questionnaire that she has cataracts, floaters, and dry eyes
 - does not check off or otherwise indicate eye pain, vision blur, vision loss or other symptoms
- Pt 'friends' with OD's parents- feels entitled to 'special treatment'
 - No waiting room or copays for her!
- OD flustered by pt 'barking' at her
- Performs IOP- normal, but not recorded



Case: Running afoul of a crazy person

- Successful dilation and stereoscopic evaluation of the optic nerves was performed and recorded as normal without suspicion of glaucoma. The patient was correctable to 20/20 in each eye following a thorough examination.

Case: Running afoul of a crazy person

- Pt returns 1 year for annual exam
- The patient does not complain of ocular pain or vision loss.
- Intraocular pressure by applanation is normal at this visit.
- A dilated fundus examination is successfully performed without precipitating an angle closure attack. There is no evidence of abnormality other than advancing age-appropriate cataracts

Case: Running afoul of a crazy person

- PT RTC 1 mos later complaining of blurred vision that had occurred 2 days previously, but had since resolved.
- The patient appears to have mentioned elevated blood pressure at this time.
- The anterior chamber was judged to be deep and quiet and the patient was successfully dilated again without precipitating an angle closure attack. No signs consistent with glaucoma were found upon examination.

Case: Running afoul of a crazy person

- Dr. diagnosed ocular surface abnormalities as a possible cause of the patient's transiently blurred vision and recommended lubrication as well as a referral to a primary care evaluation for a hypertension evaluation.
 - Pt diagnosed and now treated for HTN ☹️
- PCP orders MRI to determine the cause of the patient's transiently obscured vision
 - MRI normal

Case: Running afoul of a crazy person

- 10 mos later, pt visits ophthalmologist who diagnoses 'narrow angle glaucoma'.
- MD examination details normal optic discs, normal retinal nerve fiber layer, and a normal GDx evaluation. Threshold perimetry done on this date also normal
 - Likely MD was using the antiquated term, "narrow angle glaucoma" to connote a potentially occludable angle.
 - Intraocular pressure at that visit was not in keeping with true angle closure.

Case: Running afoul of a crazy person

- Gonioscopy indicated potentially occludable angles and MD appropriately recommended laser iridotomy
 - Successful
- Interval of 10 months between the examinations
 - cataractogenesis process during this interval could easily increase pupil block and initiate narrowing of the anterior chamber angle, which may have not been present and observable to optometrist at the time of her last examination.

Case: Running afoul of a crazy person

- Pt quite agitated with optometrist for not 'diagnosing her glaucoma'
 - After all, pt needed surgery!
 - Prophylactic LPI
- Claims negligence against OD
 - Pain and suffering and mental anguish
 - Her life is 'ruined'
 - Negligent care
 - Misdiagnosis leads to vision loss
 - Nothing documentable

Case: Running afoul of a crazy person

- Pt claims she has sought counsel of several lawyers but doesn't 'want to go that way'
 - Translation:
- Pt send threatening letter to OD demanding refund of all fees, copays, and remuneration for 'pain and 'suffering' or she will 'avail herself of all legal means'
- Gives actual dollar amount for compensation
- Translation:
- OD seeks counsel
- Pt vindictively* reports OD to Board

* Personal editorial



Case: Running afoul of a crazy person

- Pt dilated twice- Stereoscopic disc analysis, BIO
- Pt treated appropriately for OSD, refractive error
- Pt referred for evaluation and diagnosed with HTN and treated
- *Sole issue: during 1 exam, under duress, OD did not record IOP*
 - OD admission- knew IOP could have been added and none of this would have happened, but knew it wasn't right thing to do
 - Did perform dilation and BIO and disc analysis at visit

Case: Running afoul of a crazy person

- Charge: Violation of Chapter 463.005 Rule 64B13-3.007 Minimum Procedures for Vision Analysis
 - Did not perform tonometry and 'specific glaucoma test'
- Board retains expert
- OD and attorney retain me as expert

The Facts as I See Them

- Tonometry is not, in fact, a "glaucoma test" or "specific glaucoma test", but merely the measurement of IOP
- Elevated intraocular pressure is a risk factor for glaucoma, but not in itself a diagnosis of glaucoma.
- Tonometry is not even an accepted screening test for glaucoma
 - Tonometry is not specific enough a test to screen for glaucoma as many patients with the disease can be mis-labeled as normal
- Detailed stereoscopic evaluation of the optic disc is a more sensitive measurement for the determination of glaucoma
 - Ergo, the OD did do a 'specific glaucoma test'

The Facts as I See Them

- No permanent damage sustained by the patient.
- No evidence that any of the patient's complaints were attributable to intermittent angle closure.
- The patient was determined to merely have potentially occludable angles.
- The patient successfully underwent laser iridotomy, which has presumably reduced the risk of future occlusion.

The Facts as I See Them

- The same procedure would have been necessary had the potentially occludable state been diagnosed by any other qualified doctor at any time.
- Thus, the patient has received the proper treatment.
- There is nothing in any records reviewed that indicate the actions or alleged inactions of optometrist negatively impacted the apparently positive outcome for this patient.

The Facts as I See Them

- OD delivered excellent care in face of adversity
- OD was professional in not altering record
- OD sought legal counsel

Final Outcome

- Case dismissed for no probable cause

Case: Alleged Negligence

- Lawn/ tree service worker presents with corneal abrasion
 - No hx of vegetative matter given
 - 3 days of FB sensation; no complaints of vision loss
- Geographic abrasion and edema without infiltration
 - Treated with Maxitrol and bandage CL- f/u 2 days
 - RTC immediately if any changes
- Pt returns 2 days later with severe central corneal infiltration
- OD recognizes possibility of fungal infection- tries to refer immediately

Case: Alleged Negligence

- Pt wants to 'wait to see if it gets better'
- Workers comp- referral authorization will take 'at least a week'
- OD adamant- explains fungal infection and permanent vision loss
- Pt ultimately referred and seen next day and treated for bacterial keratitis despite OD note about fungus
- After 7-10 days of not improving, pt referred elsewhere and dx'ed with fungal keratitis

Case: Alleged Negligence

- Pt initiates litigation against OD
- Referral center recognized issue and offered compensation in advance of litigation, so was not sued
- Pt leaves country, not participating in legal process- case dies
- Pt's attorney vindictively* reports OD to DOH for license sanctions

*personal editorial

Case: Alleged Negligence

- DOH Expert:
 - OD violated Chapter 463.0135(1) by failing to provide the degree of medical care provided by similarly trained medical practitioners in the same or similar communities
 - Treated corneal abrasion with antibiotic-steroid combination
 - Use of antibiotics alone is standard of care
 - Using steroid for vegetative corneal injury
 - Failed to timely refer fungal keratitis

The Facts as I See Them

- No hx of vegetative injury ever given by pt to anyone
 - DOH broad speculation based upon employment and final diagnosis
- Steroid-antibiotic combo reasonable for corneal abrasion
- No indication of fungal keratitis at first visit
 - Prophylactic natamycin? Refer abrasion to corneal specialist? What more could OD do?
- OD was first to consider fungus, but nobody listened
- What would have happened if OD used standard of care treatment with topical antibiotics alone?

Final Outcome

- Case dismissed for no probable cause

“There is no bad referral?”

- OD sees patient with progressive vision loss after solar eclipse
- 20/50 vision OS
- Pt told had to see ophthalmologist STAT due to potential for blindness for “large cups in nerve”
 - 0.7/0.7 C/D OU
- On call ophthalmologist for ER reports OD for ‘patient dumping’.

Do as I say...or else

- Female presents to OD
- Demands 1 year refills on timolol
- Refuses any additional testing or follow up
- Doctor declines...gets reported to DOH

Another RD Case

- Pt c/o floaters
- Examined by OD who dilates, performs BIO, finds retina intact, warns Si/Sx RD; RTC ASAP any changes
- Pt experiences vision reduction on a Thursday, somewhat worse on Friday- wants to see if it will ‘clear up’
- Comes in Monday with macula off RD
- Sues OD
- Expert witness: “*He didn’t look well enough*”
- Attorney invokes following statute:

Another RD Case

- (4) A licensed practitioner shall promptly advise a patient to seek evaluation by a physician skilled in diseases of the eye and licensed under chapter 458 or chapter 459 for diagnosis and possible treatment whenever the licensed practitioner is informed by the patient of the sudden onset of spots or “floaters” with loss of all or part of the visual field.
- Defense attorney flustered by rule
 - Retained to defend OD

Why is this so?

- Do I have to refer every case of flashes and floaters?
- Difference between licensed practitioner (who cannot dilate) and certified practitioner (who can dilate).
- These patients need dilation- licensed practitioner can’t and certified can.
 - If RD found- pt logically referred
 - If nothing seen but pt has vision loss- pt logically referred
- Why no statute regarding older patient with headache and jaw claudication, etc?

Standards of Practice

- (2) A licensed practitioner diagnosing angle closure, infantile, or congenital forms of glaucoma shall refer the patient to a physician skilled in diseases of the eye and licensed under chapter 458 or chapter 459.

Why is this so?

- Acute angle closure, infantile, and congenital forms of glaucoma are primarily surgical diseases.
- Forces non-surgeons from "Forrest Gumping their way through" medically

Responsibility

A licensed practitioner shall have an established procedure appropriate for the **provision of eye care to his/her patients in the event of an emergency outside of normal professional hours, and when the licensed practitioner is not personally available.** Since the licensed practitioner's continuing responsibility to the patient is of a personal professional nature, no licensed practitioner shall primarily rely upon a hospital emergency room as a means of discharging this responsibility.

So what does this mean to you?

- Unlike every other medical provider, your answering machine cannot say, *"If this is a medical emergency, hang up and dial 911"*
- You must have an on-call system after hours; The system cannot direct patients to the ER.
- Options: your cell phone #, professional answering service with your cell phone #, a colleague or practice/ institution who will accept your emergencies
- Note: you have no obligation to provide after hours emergency care to any person who is **NOT** your patient
 - Caveat: neither does your ophthalmology colleagues

- (3) When an infectious corneal disease condition has not responded to standard methods of treatment within the scope of optometric practice, the certified optometrist shall consult with a physician skilled in diseases of the eye and licensed under chapter 458 or chapter 459.

So what does this mean to you?

- Duh!
- Do we really have to explain it?

64B13-3.010 Standards of Practice.

- (2) An optometrist shall not use or perform any technique, function, or mode of treatment which the optometrist is not professionally competent to perform. Professional competence as used in this rule may be acquired by formal education, supervised training and experience, continuing education programs which have been approved by the Board, or an appropriate combination of such means.



64B13-3.010 Standards of Practice.

- (4) Certified optometrists employing the topical ocular pharmaceuticals listed in subsection 64B13-18.002(9), F.A.C., Anti-Glaucoma Agents, shall comply with the following:
- (a) Upon initial diagnosis of glaucoma of a type other than those specifically listed in Section 463.0135(2), F.S., the certified optometrist shall develop a plan of treatment and management.
1. The plan will be predicated upon the severity of the existing optic nerve damage, the intraocular pressure, and stability of the clinical course.
- In the event the certified optometrist cannot otherwise comply with the requirements of subsections 64B13-3.010(1)-(3), F.A.C., a co-management plan shall be established with a physician skilled in the diseases of the human eye and licensed under Chapter 458 or 459, F.S.

So what does this mean to you?

- Not much different than what you are already doing.
- If you diagnose glaucoma, make a treatment plan
- If glaucoma is bad, make it an aggressive plan.
- If you can't, send it to someone who can

Standards of Practice

- (b) Because topical beta-blockers have potential systemic side effects a certified optometrist employing beta-blockers shall, in a manner consistent with Section 463.0135(1), F.S., ascertain the risk of systemic side effects through either a case history that complies with paragraph 64B13-3.007(2)(a), F.A.C., or by communicating with the patient's primary care physician. The certified optometrist shall also communicate with the patient's primary care physician, or with a physician skilled in diseases of the eye and licensed under Chapter 458 or 459, F.S., when, in the professional judgment of the certified optometrist, it is medically appropriate to do so. This communication shall be noted in the patient's permanent record. The methodology of communication is left to the professional discretion of the certified optometrist.

So what does this mean to you?

- When in doubt...ask
- You are not obligated to tell the PCP that you have prescribed a beta blocker... but it is good care and a courtesy
- Easy way- write the Rx and tell the patient to show to PCP before filling.

Standards of (Glaucoma) Practice

- (c) The certified optometrist shall have available, and be proficient in the use of, the following instrumentation:
1. Goldman-type applanation tonometer.
 2. Visual fields instrumentation capable of threshold perimetry.
 3. Gonioscope.
 4. Fundus Camera or detailed sketch of optic nerve head.
 5. Biomicroscope.
 6. A device to provide stereoscopic view of optic nerve.

Hmmm... still no pachymeter, camera, or OCT

- (9) A licensed practitioner who believes a patient may have glaucoma shall promptly advise the patient of the serious nature of glaucoma. The licensed practitioner shall place in the patient's permanent record that the practitioner provided such advice to the patient.

- (4) A licensed practitioner shall promptly advise a patient to seek evaluation by a physician skilled in diseases of the eye and licensed under chapter 458 or chapter 459 for diagnosis and possible treatment whenever the licensed practitioner is informed by the patient of the sudden onset of spots or "floaters" with loss of all or part of the visual field.

Why is this so?

- Do I have to refer every case of flashes and floaters?
- Difference between licensed practitioner (who cannot dilate) and certified practitioner (who can dilate).
- These patients need dilation- licensed practitioner can't and certified can.
 - If RD found- pt logically referred
 - If nothing seen but pt has vision loss- pt logically referred
- Why no statute regarding older patient with headache and jaw claudication, etc?

463.0135 Standards of practice.—

- (1) A licensed practitioner shall provide that degree of care which conforms to that level of care provided by medical practitioners in the same or similar communities. A licensed practitioner shall advise or assist her or his patient in obtaining further care when the service of another health care practitioner is required.

- (5) The licensed practitioner shall routinely advise a patient to immediately contact the licensed practitioner if the patient experiences an adverse drug reaction.
- (6) The licensed practitioner shall, when appropriate, refer to medical specialists or facilities patients who notify a licensed practitioner of an adverse drug reaction.
- (7) The licensed practitioner shall place in a patient's permanent record information describing any adverse drug reaction experienced by the patient, the date of such reaction, and whether any referral was made.

- (8) The licensed practitioner shall maintain the names of at least three physicians, physician clinics, or hospitals to whom the licensed practitioner will refer patients who experience an adverse drug reaction. At least one of these physicians shall be a physician skilled in the diagnosis and treatment of diseases of the eye and licensed under chapter 458 or chapter 459.

Responsibility

A licensed practitioner shall **give notice** to the patient when he or she relocates his or her practice or withdraws his or her services so that the patient may make arrangements for his or her eye care. Notice to the patient shall specifically identify the new location of the licensed practitioner's practice or the location at which the patient may obtain his or her patient record, and shall be in compliance with Rule 64B13-3.003, F.A.C.

So what does this mean to you?

- You have to let them know when you and your practice cease
- Caveat:
 - Covering offices of "Dr. Smith and associates"
 - The practice remains open
 - Pt records are still at that practice
 - Can post notice of departure

Responsibility

Patient records shall clearly identify the optometrist who examined or treated the patient on each separate occasion.

So what does this mean to you?

- Sign the chart
- Make sure EHR drops signature correctly
- This has been an issue in Board cases and malpractice litigation

Patient Records

64813-3.003 Patient Records; Transfer or Death of Licensed Practitioner.

- (1) The licensed practitioner must **legibly sign** the entry in his or her records for each patient encounter. If the practitioner maintains electronic patient records, the practitioner may affix an electronic signature which can be generated by using either public key infrastructure or signature dynamics technology, and meets the following criteria:
- (a) The electronic signature is unique to the person using it;
 - (b) The electronic signature is capable of verification;
 - (c) The electronic signature is under the sole control of the person using it;
 - (d) The electronic signature is linked to the record in such a manner that the electronic signature is invalidated if any data in the record are changed.

Patient Records

- (2) A licensed practitioner shall maintain full and independent responsibility and control over all records relating to his or her patients and his or her optometric practice. All such records shall remain confidential except as otherwise provided by law and shall be maintained by the licensed practitioner in compliance with Rule 64813-3.001, F.A.C. For the purposes of this rule, "maintain full and independent responsibility and control" means that the records shall be maintained in the licensed practitioner's office or solely in the possession of the licensed practitioner, and that the licensed practitioner shall not share, delegate, or relinquish either possession of the records or his or her responsibility or control over those records with or to any entity which is not itself a licensed practitioner.

Patient Records

- (3) The records relating to the patients of a multidisciplinary group of licensed health care professionals as provided in Section 463.014(1)(a), F.S., or relating to the patients of a partnership or professional association as provided in Section 463.014(1)(b), F.S., **may be maintained by the group practice, partnership, or professional association on behalf of all licensed practitioners employed by the group practice, partnership, or professional association.**
- (4) For the purposes of this rule, "entity which itself is not a licensed practitioner" shall refer to any corporation, lay body, organization, individual, or commercial or mercantile establishment which is not a licensed practitioner or which is not comprised solely of licensed health care professionals, the primary objective of whom is the diagnosis and treatment of the human body.

Patient Records

(5) For the purposes of this rule, "commercial or mercantile establishment" shall include an establishment in which the practice of opticianry is conducted pursuant to Chapter 484, Part I, Florida Statutes, and an establishment in which optical goods are sold.

(6) A licensed practitioner shall keep patient records for a period of at least five years after the last entry. Upon the discontinuance of his or her practice, the licensed practitioner shall either transfer all patient records which are less than five years old to an eye care practitioner licensed pursuant to Chapter 463, 458, or 459, F.S., where they may be obtained by patients, or he or she shall keep them in his or her possession for at least five years and make them available to be obtained by patients.

So what does this mean to you?

- The records are yours, not the optician's, not Lenscrafters, etc.
- Keep them for 5 years after last visit
- Hand them off to a colleague if pt active and records less than 5 years old

Records at Death

(7) A licensed practitioner who retires or otherwise discontinues his or her practice shall cause to be published in the newspaper of greatest general circulation in each county where the licensed practitioner practiced, a notice indicating to his or her patients that the licensed practitioner's patient records are available from a specified eye care practitioner licensed pursuant to Chapter 458, 459, or 463, F.S., at a certain location. The notice shall be published once during each week for four (4) consecutive weeks. A copy of the published notice shall be delivered to the Board office for filing.

Records at Death

(8)(a) The executor, administrator, personal representative, or survivor of a deceased licensed practitioner shall retain patient records concerning any patient of the deceased licensed practitioner for at least five years from the date of death of the licensed practitioner.

(b) Within one (1) month from the date of death of the licensed practitioner, the executor, administrator, personal representative, or survivor of the deceased licensed practitioner shall cause to be published in the newspaper of greatest general circulation in each county where the licensed practitioner practiced, a notice indicating to the patients of the deceased licensed practitioner the location at which those patients may obtain their patient records. The notice shall be published once during each week for four (4) consecutive weeks. A copy of the published notice shall be delivered to the Board office for filing.

So what does this mean to you?

- If you are retiring, you should make patients aware as soon as plans are made
- Additionally, you have to make patients aware after retirement that they can get their records and how
- After your death, does it really matter? What exactly can be done to you? You can't be brought up on charges and the Board and DOH have no governance over your spouse.

Entrance Sign

- Whenever a licensed practitioner is actively engaged in the practice of optometry, or actively holding himself or herself out as a practitioner, he or she shall cause to be placed or kept in a conspicuous place at each entrance to each office a sign which lists each licensed practitioner's name and words of proper abbreviation or intelligible lettering clearly denoting that the practitioner is engaged in the practice of optometry.
- "Practice Limited to the Eye" is not acceptable